Procter & Gamble Hygiene and Health Care has filed its Business Responsibility & Sustainability Report (BRSR) for the financial year ended March 31, 2026. The filing, dated August 17, 2026, outlines the company’s operational metrics, environmental impact, and corporate social responsibility initiatives for FY26.

The company reported a turnover of ₹4,290 crore and a net worth of ₹754 crore for the period. Sanitary napkins accounted for 65% of its product mix, while healthcare products contributed 33%. Exports constituted 3.19% of total turnover, with products reaching 14 countries.

Environmental Metrics

Procter & Gamble Hygiene and Health Care reported nil market-based Scope 2 greenhouse gas emissions for FY26, including the application of Renewable Energy Certificates. The company achieved 5,659 kilolitres of circular water usage through condensate recovery and internal effluent treatment plant recycling.

The Goa manufacturing plant maintained its status as a zero-manufacturing-waste-to-landfill site. The company continues to comply with Extended Producer Responsibility (EPR) guidelines for plastic packaging waste collection.

Workforce and Governance

As of March 31, 2026, the company employed 241 permanent employees and 471 workers. Women represented 36% of permanent employees and 4% of workers. At the board level, women held 22.22% of seats, while 33.33% of Key Managerial Personnel were female.

The company’s flagship CSR program, P&G Shiksha, has impacted over 1 crore children since its inception in 2005. The initiative focuses on improving learning outcomes and supporting at-risk communities across India.

What the Numbers Show

The complete absence of market-based Scope 2 emissions indicates full offsetting or renewable energy procurement for indirect electricity use. This aligns with the company’s stated ambition to reduce its environmental footprint while maintaining operational scale across 28 states and 8 union territories.

Procter & Gamble Hygiene and Health Care reported a net profit of ₹857 crore for the financial year ended March 31, 2026, an increase from ₹637 crore in the previous period. Revenue from operations rose to ₹4,290 crore, up from ₹3,374 crore in the prior year. The previous financial year (FY25) was a nine-month period due to the company’s shift in fiscal calendar, making direct year-on-year comparisons less precise.

The Board of Directors recommended a final dividend of ₹60 per equity share for FY26. This follows an interim dividend of ₹195 per share, which included a one-time special dividend of ₹25 per share, paid in February 2026. The aggregate dividend for the year amounts to ₹255 per share, subject to shareholder approval at the 62nd Annual General Meeting.

Financial Performance

The company’s profitability metrics showed significant improvement alongside top-line growth. Profit before tax stood at ₹1,167 crore, compared to ₹862 crore in the previous period. Earnings per share increased to ₹264 from ₹196 in the prior year.

What the Numbers Show

The improvement in net profit margin is notable. In FY26, the net profit margin expanded to approximately 20%, up from 19% in the previous nine-month period. This suggests that cost management or operational efficiencies may have contributed to bottom-line growth outpacing revenue growth. Additionally, the return on capital employed improved to 1.35 from 1.03, indicating better utilization of capital.

Operational Highlights

The company continued its focus on innovation across feminine care and healthcare portfolios. Key brands include Whisper and Vicks. The Whisper Period Panty portfolio and Vicks VapoRub were highlighted as strong performers. The company also launched Vicks Cough Syrup, targeting the herbal remedy segment, and upgraded Zzzquil Natura Sleep Gummies.

Corporate Governance

Several changes occurred in the board and management structure during the year. Mr. Gagan Sawhney stepped down as Non-Executive Director in October 2025. Ms. Mrinalini Srinivasan ceased to be Chief Financial Officer in June 2025, succeeded by Mr. Gaurav Bhartia. Post-closure of the financial year, Ms. Srividya Srinivasan was appointed as Whole-time Director and CFO effective July 1, 2026.

The 62nd Annual General Meeting will be held on September 8, 2026, via video conference. Shareholders will vote on the re-appointment of Mr. Pramod Agarwal and the appointment of Ms. Srividya Srinivasan.